🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
These laboratory trial studies the development and treatment of a mouse mod...
Status
Completed
Location
Children's Oncology Group
Start Date
2012-05
Trial ID
NCT01576185
Treatments Being Tested
The purpose of this study is to define a safe dose of AC220 when given as m...
Status
Completed
Location
City of Hope
Start Date
2012-04
Trial ID
NCT01468467
Treatments Being Tested
This study will be a randomized, open-label, pretest post-test with two stu...
Status
Completed
Location
Shaimaa Mohamed Ahmed El Sayeh
Start Date
2023-03-10
Trial ID
NCT05849701
Treatments Being Tested
This phase I/II trial studies the side effects and best dose of quizartinib...
Status
Completed
Location
M D Anderson Cancer Center
Start Date
2013-11-12
Trial ID
NCT01892371
Treatments Being Tested
The AML18 Pilot Trial will evaluate the feasibility of three interventions ...
Status
Completed
Location
Aberdeen Royal Infirmary
Start Date
2011-04
Trial ID
NCT01236144
Treatments Being Tested
This is a phase I study of the investigational drug AC220 combined with cyt...
Status
Completed
Location
Childrens Hospital Los Angeles
Start Date
2011-09-01
Trial ID
NCT01411267
Treatments Being Tested
This is a Phase 2, multi-center, open-label study to evaluate the efficacy,...
Status
Completed
Location
Multiple Locations
Start Date
2016-12-08
Trial ID
NCT02984995
Treatments Being Tested
The purpose of this study is to define the maximum tolerated dose (MTD) of ...
Status
Completed
Location
Mayo Clinic Jacksonville
Start Date
2011-10
Trial ID
NCT01390337
Treatments Being Tested
This phase I/II trial studies the side effects and how well cladribine, ida...
Status
Recruiting
Location
M D Anderson Cancer Center
Start Date
2019-10-22
Trial ID
NCT04047641
Treatments Being Tested
AC220 will be administered as a once daily oral solution given continuously...
Status
Completed
Location
Dana Farber Cancer Institute
Start Date
2010-01
Trial ID
NCT01049893
Treatments Being Tested